FDA APPROVES MEDTRONIC PERCEPT™ RC NEUROSTIMULATOR WITH EXCLUSIVE BRAINSENSE™ TECHNOLOGY

Medtronic announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system. The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology, and SenSight™ directional leads. The Percept™ family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinson's disease, essential tremor, and dystonia as well as epilepsy. Over 11 million people in the U.S. are living with movement disorders and approximately 3.4 million with epilepsy.

DBS uses a surgically implanted medical device, similar to a cardiac pacemaker. Medtronic Percept™ neurostimulators transmit electrical signals via slender wires to specific brain targets affected by debilitating neurological disorders like Parkinson's disease.

Percept™ RC is the smallest and thinnest dual channel‡ neurostimulator available for DBS. It is equipped with BrainSense™ technology that captures and records brain signals to provide insights that enable a healthcare provider to adapt and personalize therapy to a patient's evolving needs. Unlike other rechargeable devices, the Percept™ RC battery offers at least 15 years of service life with consistent and fast recharge performance. Medtronic patented battery technology has less battery fade than other rechargeable devices for a more reliable, long-lasting battery. Patients can experience rapid recharging from 10% to 90% full charge in less than an hour.

Percept™ offers greater freedom and scan access for patients with 3T scans and best-in-class 1.5T MRI scan labelling. Medtronic has the only DBS system that allows patients to have stimulation on in bipolar mode during an MRI. In addition, the Percept™ neurostimulators are engineered to allow for future software updates designed for the Percept™ platform without a neurostimulator device exchange.

For further information on the Percept™ neurostimulators with exclusive BrainSense™ technology, visit our website here.